Results 101 to 110 of about 180 (117)

Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®

Case Medical Research, 2019
openaire   +1 more source

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets

European Journal of Neurology, 2023
Marco Battaglini, Rosa Cortese, Nektaria Alexandri   +2 more
exaly  

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study

Multiple Sclerosis Journal, 2022
Gavin Giovannoni, Patrick Vermersch, Dominic Jack   +2 more
exaly  

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Case Medical Research, 2019
openaire   +1 more source

Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study

Multiple Sclerosis and Related Disorders, 2023
exaly  

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

Multiple Sclerosis and Related Disorders, 2019
Gavin Giovannoni, Per Soelberg Sorensen, Giancarlo Comi   +2 more
exaly  

Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis

Multiple Sclerosis and Related Disorders, 2020
Gavin Giovannoni, Xavier Montalbán, Giancarlo Comi   +2 more
exaly  

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

Expert Opinion on Pharmacotherapy, 2013
Hans-Peter Hartung, Giancarlo Comi, Steven J Greenberg   +2 more
exaly  

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Multiple Sclerosis Journal, 2018
Gavin Giovannoni, Per Soelberg Sorensen, Giancarlo Comi   +2 more
exaly  

Safety and tolerability of cladribine tablets in multiple sclerosis: in the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

2011
Cook S, Vermersch P, COMI , GIANCARLO, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group   +13 more
openaire   +1 more source